NightHawk Biosciences Stock Analysis & Ratings
0 Followers
1HB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.60 - €7.63
Previous Close€2.17
Volume0.00
Average Volume (3M)487.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta0.29
Next EarningsNov 14, 2022
EPS Forecast-€0.26
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target€7.94
Smart Score2
EPS (TTM)N/A
Shares Outstanding25,649,824
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume487
P/B Ratio0.62
P/S Ratio47.04
P/CF RatioN/A
P/FCF Ratio-1.70
Total Debt€1.63M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside265.25% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering1
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
1HB FAQ
What was NightHawk Biosciences’s price range in the past 12 months?
NightHawk Biosciences lowest stock price was €1.60 and its highest was €7.63 in the past 12 months.
What is NightHawk Biosciences’s market cap?
Currently, no data Available
What is NightHawk Biosciences’s price target?
The average price target for NightHawk Biosciences is €7.94. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is €7.94 ,the lowest forecast is €7.94. The average price target represents 265.25% Increase from the current price of €2.174.
The highest analyst price target is €7.94 ,the lowest forecast is €7.94. The average price target represents 265.25% Increase from the current price of €2.174.
What do analysts say about NightHawk Biosciences?
NightHawk Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is NightHawk Biosciences’s upcoming earnings report date?
NightHawk Biosciences’s upcoming earnings report date is Nov 14, 2022 which is in 86 days.
How were NightHawk Biosciences’s earnings last quarter?
NightHawk Biosciences released its earnings results on Aug 10, 2022. The company reported -€0.397 earnings per share for the quarter, missing the consensus estimate of -€0.298 by -€0.099.
Is NightHawk Biosciences overvalued?
According to Wall Street analysts NightHawk Biosciences’s price is currently Undervalued.
Does NightHawk Biosciences pay dividends?
NightHawk Biosciences does not currently pay dividends.
What is NightHawk Biosciences’s EPS estimate?
NightHawk Biosciences’s EPS estimate is -€0.26.
How many shares outstanding does NightHawk Biosciences have?
Currently, no data Available
What happened to NightHawk Biosciences’s price movement after its last earnings report?
NightHawk Biosciences reported an EPS of -€0.397 in its last earnings report, missing expectations of -€0.298. Following the earnings report the stock price went up 1.035%.
Which hedge fund is a major shareholder of NightHawk Biosciences?
Currently, no hedge funds are holding shares in DE:1HB
---
NightHawk Biosciences Stock Analysis
Smart ScoreUnderperform
1
2
3
4
5
6
7
8
9
10
Analyst Forecast
Moderate Buy
Average Price Target: €7.94
Blogger Sentiment
N/A
Currently Not Enough Data Available
Insider Transactions
N/A
Currently Not Enough Data Available
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.50%
12-Months-Change
Fundamentals
Return on Equity
-34.45%
Trailing 12-Months
Asset Growth
-5.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NightHawk Biosciences
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
---
---